Evidence map›Paper›PMID 32055023›Full record

ArticleOncogene2020

Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.

Adrian M Seifert, Charlotte Reiche, Max Heiduk, Anna Tannert, Ann-Christin Meinecke, Stephanie Baier, Janusz von Renesse, Christoph Kahlert, Marius Distler, Thilo Welsch and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Methanol Extract fromAntioxidants (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.International journal of molecular sciences · 2025
    Review
  17. Review
  18. Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells.Apoptosis : an international journal on programmed cell death · 2025
    Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Adrian M Seifert *Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-5329-3164
Charlotte Reiche *Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Max HeidukDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Anna TannertDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Ann-Christin MeineckeDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Stephanie BaierDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Janusz von RenesseDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Christoph KahlertDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Marius DistlerDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Thilo WelschDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Christoph ReissfelderDepartment of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Daniela E AustDepartment of Pathology, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
George MillerS.A. Localio Laboratory, Department of Surgery, New York University School of Medicine, New York, NY, USA.
Jürgen WeitzDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany.
Lena SeifertDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, University of Dresden, Dresden, Germany. lena.seifert@ukdd.de.
University Hospital Carl Gustav Carus · DEGerman Cancer Research Center · DEHeidelberg University · DENew York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1. Galectin-9, a β-galactoside-binding lectin, promotes immune suppression through T-cell inhibition, and programming of tolerogenic macrophages. Of all cancers tested, PDAC showed the highest expression of LGALS9 (galectin-9) mRNA. We analyzed formalin-fixed and paraffin-embedded specimens from 83 patients with PDAC stained for galectin-9. Using flow cytometry, we determined galectin-9 expression on immune cells from tumor and matched blood samples from 12 patients with resectable PDAC. Furthermore, we analyzed galectin-9 serum levels by enzyme-linked immunosorbent assay using serum samples from 70 patients with PDAC, from 36 individuals with benign pancreatic disease, and from 28 healthy controls. Galectin-9 was highly expressed in human PDAC compared with normal pancreas and present on both tumor and immune cells. Tumor-infiltrating immune cells, especially CD3

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Pancreatic DuctalCohort StudiesFemaleGalectinsHumansIntraepithelial LymphocytesMaleMiddle AgedNeoplasm StagingPancreasPancreatic NeoplasmsPrognosisSurvival AnalysisBiomarkers, TumorGalectinsLGALS9 protein, human

Identifiers

PMID32055023
PMCPMC7142017
OpenAlexW3006276127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.